Trends in high-risk rates and screening rates for the population-based cancer screening program on esophageal, stomach and liver cancer in China, 2010-2016

被引:26
作者
Li, Jiang [1 ]
Li, He [1 ]
Zeng, Hongmei [2 ]
Zheng, Rongshou [2 ]
Cao, Maomao [1 ]
Sun, Dianqin [1 ]
He, Siyi [1 ]
Ren, Jiansong [1 ]
Chen, Wanqing [1 ]
He, Jie [3 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp,Off Canc Screening, Beijing 100021, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp,Off Canc Registry, Beijing 100021, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp,Dept Thorac Surg, Beijing 100021, Peoples R China
来源
JOURNAL OF THE NATIONAL CANCER CENTER | 2021年 / 1卷 / 03期
基金
国家重点研发计划;
关键词
High; -risk; Screening; Esophageal cancer; Stomach cancer; Liver cancer; NEGATIVE BREAST-CANCER; PLUS CHEMOTHERAPY CHEMO; PHASE-III; PEMBROLIZUMAB PEMBRO; PATIENTS PTS; PD-L1; EXPRESSION; NAB-PACLITAXEL; DOUBLE-BLIND; RESISTANCE; THERAPY;
D O I
10.1016/j.jncc.2021.05.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A population-based cancer screening program in rural China, targeting three types of cancer that are most prevalent in these areas, including esophageal, stomach, and liver cancer was awarded by the government in China since 2007. A two-step design with cancer risk assessment based on questionnaire interview and HBsAg test strip and subsequent clinical intervention for high-risk populations was adopted with free of charge at the local hospitals designated in the program. The participate rate including high-risk rates and screening rates was important to find appropriate strategies to improve the overall awareness of the program.Methods: Data from the cancer screening program between 2010 and 2016 were used to calculate higher rate (high-risk population/ participants recruited) and screening rate (participants received screening/ high-risk pop-ulation).Results: From 2010 to 2016, 1,637,429 residents were recruited in the program and filled the questionnaires, 350,646 (21.4%) for esophagus cancer, 273,715 (16.7%) for stomach cancer and 1,013,068 (61.9%) for liver can-cer. 471,974 participants were assessed as high-risk population including 114,786 (24.3%) high risk for esophagus cancer, 161,809 (34.3%) high risk for stomach cancer and 195,379 (41.4%) high risk for liver cancer, respec-tively. 249,185 (52.8%) participants who were assessed as high risk received clinical screening. There were 64,710 (26.0%) for esophagus cancer screening, 71,365 (28.6%) for stomach cancer screening and 113,110 (45.4%) for liver cancer screening, respectively.Conclusion: Our findings will provide important references for designing effective population-based screening strategies to enhance the screening acceptance by health action plan in the future.
引用
收藏
页码:101 / 107
页数:7
相关论文
共 83 条
[1]   Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment [J].
Azizi, Elham ;
Carr, Ambrose J. ;
Plitas, George ;
Cornish, Andrew E. ;
Konopacki, Catherine ;
Prabhakaran, Sandhya ;
Nainys, Juozas ;
Wu, Kenmin ;
Kiseliovas, Vaidotas ;
Setty, Manu ;
Choi, Kristy ;
Fromme, Rachel M. ;
Phuong Dao ;
McKenney, Peter T. ;
Wasti, Ruby C. ;
Kadaveru, Krishna ;
Mazutis, Linas ;
Rudensky, Alexander Y. ;
Pe'er, Dana .
CELL, 2018, 174 (05) :1293-+
[2]   Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel? [J].
Bai, Xupeng ;
Ni, Jie ;
Beretov, Julia ;
Graham, Peter ;
Li, Yong .
CANCER LETTERS, 2021, 497 :100-111
[3]   Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer [J].
Bardia, A. ;
Mayer, I. A. ;
Vahdat, L. T. ;
Tolaney, S. M. ;
Isakoff, S. J. ;
Diamond, J. R. ;
O'Shaughnessy, J. ;
Moroose, R. L. ;
Santin, A. D. ;
Abramson, V. G. ;
Shah, N. C. ;
Rugo, H. S. ;
Goldenberg, D. M. ;
Sweidan, A. M. ;
Iannone, R. ;
Washkowitz, S. ;
Sharkey, R. M. ;
Wegener, W. A. ;
Kalinsky, K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) :741-751
[4]   A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer [J].
Bassez, Ayse ;
Vos, Hanne ;
Van Dyck, Laurien ;
Floris, Giuseppe ;
Arijs, Ingrid ;
Desmedt, Christine ;
Boeckx, Bram ;
Vanden Bempt, Marlies ;
Nevelsteen, Ines ;
Lambein, Kathleen ;
Punie, Kevin ;
Neven, Patrick ;
Garg, Abhishek D. ;
Wildiers, Hans ;
Qian, Junbin ;
Smeets, Ann ;
Lambrechts, Diether .
NATURE MEDICINE, 2021, 27 (05) :820-+
[5]   Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade [J].
Benci, Joseph L. ;
Xu, Bihui ;
Qiu, Yu ;
Wu, Tony J. ;
Dada, Hannah ;
Twyman-Saint Victor, Christina ;
Cucolo, Lisa ;
Lee, David S. M. ;
Pauken, Kristen E. ;
Huang, Alexander C. ;
Gangadhar, Tara C. ;
Amaravadi, Ravi K. ;
Schuchter, Lynn M. ;
Feldman, Michael D. ;
Ishwaran, Hemant ;
Vonderheide, Robert H. ;
Maity, Amit ;
Wherry, E. John ;
Minn, Andy J. .
CELL, 2016, 167 (06) :1540-+
[6]   Neoadjuvant oncolytic virotherapy before surgery sensitizes triple- negative breast cancer to immune checkpoint therapy [J].
Bourgeois-Daigneault, Marie-Claude ;
Roy, Dominic Guy ;
Aitken, Amelia Sadie ;
El Sayes, Nader ;
Martin, Nikolas Tim ;
Varette, Oliver ;
Falls, Theresa ;
St-Germain, Lauren Elizabeth ;
Pelin, Adrian ;
Lichty, Brian Dennis ;
Stojdl, David Francis ;
Ungerechts, Guy ;
Diallo, Jean-Simon ;
Bell, John Cameron .
SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (422)
[7]   Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC [J].
Brockwell, Natasha K. ;
Owen, Katie L. ;
Zanker, Damien ;
Spurling, Alex ;
Rautela, Jai ;
Duivenvoorden, Hendrika M. ;
Baschuk, Nikola ;
Caramia, Franco ;
Loi, Sherene ;
Darcy, Phillip K. ;
Lim, Elgene ;
Parker, Belinda S. .
CANCER IMMUNOLOGY RESEARCH, 2017, 5 (10) :871-884
[8]   Phase II COLET study: Atezolizumab (A) plus cobimetinib (C) plus paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC). [J].
Brufsky, Adam ;
Kim, Sung-Bae ;
Zvirbule, Zanete ;
Dirix, Luc Yves ;
Eniu, Alexandru E. ;
Carabantes, Francisco ;
Izarzugaza, Yann ;
Mebis, Jeroen ;
Sohn, Joohyuk ;
Wongchenko, Matthew ;
Chohan, Saibah ;
Amin, Reena ;
McNally, V. A. ;
Miles, David ;
Loi, Sherene .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9]   Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial [J].
Buisseret, L. ;
Pommey, S. ;
Allard, B. ;
Garaud, S. ;
Bergeron, M. ;
Cousineau, I. ;
Ameye, L. ;
Bareche, Y. ;
Paesmans, M. ;
Crown, J. P. A. ;
Di Leo, A. ;
Loi, S. ;
Piccart-Gebhart, M. ;
Willard-Gallo, K. ;
Sotiriou, C. ;
Stagg, J. .
ANNALS OF ONCOLOGY, 2018, 29 (04) :1056-1062
[10]   B7 family checkpoint regulators in immune regulation and disease [J].
Ceeraz, Sabrina ;
Nowak, Elizabeth C. ;
Noelle, Randolph J. .
TRENDS IN IMMUNOLOGY, 2013, 34 (11) :556-563